Evidence map›Paper›PMID 15709027›Full record

ArticleJournal of virology2005

Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Thomas J Chambers, Xiaofeng Fan, Deborah A Droll, Edgardo Hembrador, Tiffany Slater, Michael W Nickells, Lynn B Dustin, Adrian M Dibisceglie

Abstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Hepatitis C virus: Promising discoveries and new treatments.World journal of gastroenterology · 2016
    Review
  5. Article
  6. Observational
  7. Hepatitis C virus genetic variability and evolution.World journal of hepatology · 2015
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2011
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thomas J ChambersDepartment of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis University Health Sciences Center, St. Louis, Missouri, USA. chambetj@slu.edu
Xiaofeng Fan
Deborah A Droll
Edgardo Hembrador
Tiffany Slater
Michael W Nickells
Lynn B Dustin
Adrian M Dibisceglie

Funding

Immune complexes: Origins and effects in HCV infectionR01AI060561 · NIAID · UNIVERSITY OF OXFORD · PI DUSTIN, LYNN B · 2003 to 2015
$3.9M
NIAID NIH HHS R01 AI060561NIDDK NIH HHS DK-04917NIDDK NIH HHS DK-98017
6 · The paper itself

Abstract

A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution. All patients were treatment naive and had chronic inflammation and fibrosis on biopsy. As part of an analysis of pretreatment variables that might affect the outcome of treatment, genetic heterogeneity within the viral E1-E2 glycoprotein region (nucleotides 851 to 2280) was assessed by sequencing 10 to 15 quasispecies clones per patient from serum-derived PCR products. Genetic parameters were examined with respect to response to therapy based on serum viral RNA loads at 12 weeks (early viral response) and at 24 weeks posttreatment (sustained viral response). Nucleotide and amino acid quasispecies complexities of the hypervariable region 1 (HVR-1) were less in the responder group in comparison to the nonresponder group at 12 weeks, and genetic diversity was also less both within and outside of the HVR-1, with the difference being most pronounced for the non-HVR-1 region of E2. However, these genetic parameters did not distinguish responders from nonresponders for sustained viral responses. Follow-up studies of genetic heterogeneity based on the HVR-1 in selected responders and nonresponders while on therapy revealed greater evolutionary drift in the responder subgroup. The pretreatment population sequences for the NS5A interferon sensitivity determinant region were also analyzed for all patients, but no correlations were found between treatment response and any distinct genetic markers. These findings support previous studies indicating a high level of genetic heterogeneity among chronically infected HCV patients. One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity.

Indexed as

AdolescentAdultAgedAmino Acid SequenceBase SequenceDNA, ViralFemaleGenetic VariationHepacivirusHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2MaleMiddle AgedMolecular Sequence DataDNA, ViralE1 protein, Hepatitis C virusglycoprotein E2, Hepatitis C virusInterferon-alphaInterferon alpha-2NS-5 protein, hepatitis C viruspeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRNA-Dependent RNA PolymeraseRNA, ViralViral Envelope ProteinsViral Nonstructural Proteins

Identifiers

PMID15709027
PMCPMC548442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.